Experience

Davis Polk served as special corporate disclosure counsel to the joint bookrunners on a Rule 144A/Regulation S offering by UBS Group Funding (Jersey) Limited of $1.5 billion aggregate…

Davis Polk advised Lar España Real Estate SOCIMI, S.A. (Lar España) as to U.S. and English law in connection with its offering of 19,967,756 new ordinary shares pursuant to a public rights…

Davis Polk advised the underwriters as to U.S. law in connection with the offering by Merlin Properties SOCIMI, S.A. (Merlin) of 129,212,000 new ordinary shares pursuant to a public rights…

Davis Polk advised the underwriter in connection with a concurrent SEC-registered Schedule B debt offering by KEXIM of US$125 million aggregate principal amount of its floating-rate notes…

Davis Polk advised the joint bookrunners in connection with a Rule 144A/Regulation S offering by Imperial Tobacco Finance PLC of $4.5 billion aggregate principal amount of notes guaranteed…

Davis Polk advised Capio AB (publ) on its initial public offering and listing of shares on NASDAQ Stockholm. Assuming full exercise of the overallotment option, 52,934,872 shares were sold…

Davis Polk advised Pandox Aktiebolag (publ) on its initial public offering and listing of B Shares on NASDAQ Stockholm. Assuming full exercise of the overallotment option, 60,000,000 B…

Davis Polk advised the joint global coordinators, joint bookrunners and co-lead manager in the initial public offering of 57,518,970 shares of Nordax Group AB (publ) (“Nordax”) on Nasdaq…

Davis Polk advised Biotie Therapies Corp. (“Biotie”) on its $56.7 million U.S. initial public offering of 3,806,047 American Depositary Shares (“ADSs”) representing 304,483,760 ordinary…

Davis Polk advised the dealers of a senior unsecured Rule 144A/Regulation S offering by Crédit Agricole S.A. (“Crédit Agricole”), as issuer, acting through its London branch, of series no…